The Chinese website Caixin wrote that the value of the state-owned Chinese company fell by 1.68 billion yuan ($ 248 million) after the scandal over the production of the brucellosis vaccine was revealed, which infected more than 3,200 people with it. people – he reported on Wednesday.
The share prices of China Animal Husbandry Industry Co., listed on the Shanghai Stock Exchange. fell by almost 10 percent on Tuesday. – gave the portal.
Earlier, the city of Lanzhou, the capital of Gansu province in northwest China, confirmed that antibodies against the zoonotic disease were detected in 3,245 local residents following the release of brucellosis from a pharmaceutical plant owned by the company last year.
In December 2019, the authorities first reported the leak. According to Caixin, the lack of a prompt diagnosis has prevented thousands of people from being successfully treated, leaving them with a chronic and intractable condition.
Brucellosis, also known e.g. as Maltese fever, Gibraltar fever and Rio Grande fever, it usually affects sheep, cattle, pigs and dogs. Man can become infected with it through contact with infected animal tissues or consumption of unpasteurized dairy products. There is no evidence of human-to-human transmission of bacteria.
According to Caixin, chronic brucellosis in humans is difficult to treat and causes, among other things, weakness, muscle aches and a prolonged fever. The disease is rarely fatal, but bothersome symptoms can last for months or even years. It can also lead to fertility problems.
The website describes the Lanzhou plant as an important animal disease vaccine production center accredited by the Ministry of Agriculture. According to local authorities, the brucellosis bacterium escaped from the plant because expired disinfectants were used in the plant in the summer of 2019.
In December, officials said the bacterial concentration in the plant’s leak was low, and patients should recover without treatment, Caixin said. According to the website, however, many people living in the vicinity of the plant still complain about troublesome symptoms one year after the leak.
Lanzhou medical authorities promised on Tuesday that they would oversee the pharmaceutical plant’s compensation payment, which is scheduled to begin in October and be batch-led. Details on the claims have not been released and the company has announced that the amount of the payouts has not yet been determined, the Chinese portal said.
The brucellosis vaccine production line at the Lanzhou plant was shut down in December 2019, and the plant lost its license to produce brucellosis a month later. In February, the company announced that eight people had been disciplined for the leak, the plant boss had received a warning, and his deputy had lost his job.